Product Type


Genetic testing for BRCA ½ mutations for detecting breast and ovarian cancer

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.


BRCAaccuTest™ and BRCAaccuTest™ PLUS are a reagent kit for producing libraries for analyzing the BRCA1 and BRCA2 genes using the next generation sequencing (NGS) method, which analyzes genomic DNA derived from blood or FFPE tissue.

  • For breast and ovarian cancer patients
  • For HBOC (Hereditary breast and ovarian cancer syndrome) patients
  • For family history or the age of breast cancer incidence

BRCAaccuTest™ PLUS
Certification CE-IVD
Target disease Breast/Ovarian cancer
HBOC (Hereditary breast and ovarian cancer syndrome)
Target Enrichment method Amplicon based method
Quantity 12 (6+6) test
(1 test each for control DNA)
24 test
(1 test for control DNA)
Specimen Blood, FFPE tissue, Tissue biopsy
In-put DNA quantity 10-30 ng
Target gene BRCA1 / BRCA2
Target region 22.4 kb (all protein coding region, splicing regions, selected promoter, UTR, intron regions)
amplicon 160 (2 pools)
Hands on time >5 hrs
Variants type SNV, In, Del, Dup, CNV*
NGS platform & reagent kit illumina MiSeq, MiSeq Dx / MiSeq Reagent Nano, Micro kit, v2, 300cycles
Samples throughput Germline (11) / Somatic (5) Germline (23)
Analysis solution NGeneAnalySys™ (CE)

*CNV: RUO, Research Use Only

Other information



Related Products

NgeneBio – SOLIDaccuTest™

SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

Next Generation Sequencing System – NovaSeq 6000

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Next-Generation Sequencing System – NextSeq 2000

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

NextSeq 1000 sequencing system

Product Information

Model: NextSeq 1000

Manufacturer: Illumina

Origin: Singapore/United States

Launching year: 01/2020


PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.


DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.


Next Generation Sequencing System – iSeq 100

Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.

TruSight® Tumor 26

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants

TruSight Cancer Sequencing Panel

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition